Siga Technologies (NASDAQ:SIGA) Issues Quarterly Earnings Results

Siga Technologies (NASDAQ:SIGA) issued its quarterly earnings data on Monday. The company reported ($0.04) EPS for the quarter, FiscalAI reports. The company had revenue of $1.32 million for the quarter. Siga Technologies had a negative return on equity of 1.55% and a negative net margin of 5.19%.

Here are the key takeaways from Siga Technologies’ conference call:

• U.S. procurement timing remains uncertain. SIGA said the process for a new government contract is moving more slowly than in the past, although management continues to believe an award will be made.
• SIGA signed a Canadian TPOXX contract worth up to approximately $15 million. It includes about $9 million in firm commitments over three years, with deliveries expected to begin in 2027, and up to $6 million in options.
• The PEP program’s supplemental NDA filing is now expected in 2028. FDA-requested validation and laboratory work will take additional time, delaying the filing despite SIGA’s continued view that the program is important.
• SIGA reported approximately $42 million in product revenue for the first nine months of 2026, but had no product sales in the third quarter; quarterly net loss was approximately $3 million.
• The company ended the quarter with approximately $116 million in cash and no debt, providing financial capacity amid uncertain government procurement timing.

Siga Technologies Trading Up 5.2%

SIGA stock traded up $0.16 during mid-day trading on Monday, hitting $3.26. 544,249 shares of the company were exchanged, compared to its average volume of 603,073. The firm has a fifty day simple moving average of $3.19 and a 200 day simple moving average of $4.31. The company has a market capitalization of $234.23 million, a PE ratio of -65.20 and a beta of 1.10. Siga Technologies has a twelve month low of $2.83 and a twelve month high of $7.11.

Institutional Investors Weigh In On Siga Technologies

A number of institutional investors have recently made changes to their positions in SIGA. Bank of New York Mellon Corp raised its holdings in shares of Siga Technologies by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 256,803 shares of the company’s stock worth $1,374,000 after purchasing an additional 2,635 shares during the period. Hsbc Holdings PLC raised its holdings in shares of Siga Technologies by 26.3% during the second quarter. Hsbc Holdings PLC now owns 16,904 shares of the company’s stock valued at $62,000 after buying an additional 3,519 shares during the last quarter. First Trust Advisors LP boosted its position in Siga Technologies by 3.5% during the 1st quarter. First Trust Advisors LP now owns 160,355 shares of the company’s stock worth $858,000 after acquiring an additional 5,411 shares during the period. State of Alaska Department of Revenue lifted its holdings in Siga Technologies by 34.6% in the third quarter. State of Alaska Department of Revenue now owns 24,251 shares of the company’s stock worth $82,000 after purchasing an additional 6,233 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in shares of Siga Technologies by 22.2% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 53,694 shares of the company’s stock worth $287,000 after acquiring an additional 9,772 shares during the period. 55.40% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Siga Technologies from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has an average rating of “Sell”.

About Siga Technologies

SIGA Technologies, Inc is a commercial-stage pharmaceutical company focused on developing and supplying medical countermeasures for high-consequence infectious diseases. Its primary product is TPOXX (tecovirimat), an antiviral medicine developed to treat smallpox. TPOXX targets orthopoxviruses, the virus family that includes variola virus, which causes smallpox, as well as mpox and other related infections.

TPOXX has been approved by the U.S. Food and Drug Administration in oral and intravenous formulations for the treatment of smallpox.